Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Admiral showing no signs of slowdown, says RBC

(Sharecast News) - RBC Capital Markets has hiked its target price for Admiral following the insurer's 2024 results released last week, saying the company showed "no signs of slowing down". The broker kept an 'outperform' rating on the stock, but lifted its target price from 3,550p to 3,800p.

Admiral reported on 6 March that full-year pre-tax profit was up 90% at £839.2m, as a 61% jump in UK Motor profits helped offset a more subdued performance in other divisions.

RBC said it was raising its 2025 and 2026 earnings forecasts by 8% and 6%, respectively, on the back of the results, due to better combined ratios and higher profit commissions in the UK Motor segment.

"A record year of UK Motor growth at strong margins in FY24 should sustain earnings momentum into outer years as premiums are earned through while reserve releases and profit commissions provide further support," RBC said.

With the stock trading at 15 times earnings with a dividend yield of 6%, the valuation still remains "attractive", the broker said.

Admiral's shares were up 0.9% at 3,018p by 1231 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.